Sucralfate: the Bangkok review.
Sucralfate is a site-protective ulcer healing drug with a remarkable range of mechanisms of action. Recent studies highlight the capacity of sucralfate to bind basic fibroblast growth factor (bFGF) and deliver it in high concentration to the ulcer. Basic fibroblast growth factor stimulates the production of granulation tissue, angiogenesis and re-epithelization, thus improving the quality of ulcer healing. The effect of sucralfate in reducing parietal cell sensitivity may be another factor important in the lower relapse rate demonstrated after duodenal ulcer healing. Sucralfate has been demonstrated to be efficacious in healing both duodenal and gastric ulcers together with mild oesophagitis, and it is safe for both short-term use and maintenance. In stress ulcer prophylaxis it is as effective as acid suppression or neutralization and has the advantage of lesser rates of nosocomial pneumonia than are demonstrated with antacids or H2 antagonists. The potential advantages of sucralfate lie in the better quality of ulcer healing associated with longer duration of remission.
Korman
M G
MG
Monash Medical Centre, Clayton, Victoria, Australia.
Bolin
T D
TD
Szabo
S
S
Hunt
R H
RH
Marks
I N
IN
Glise
H
H
D002986:Clinical Trials as Topic; D004381:Duodenal Ulcer / Q000188:drug therapy*; D004942:Esophagitis, Peptic / Q000188:drug therapy*; D006801:Humans; D010438:Peptic Ulcer Hemorrhage / Q000517:prevention & control; D016032:Randomized Controlled Trials as Topic; D013276:Stomach Ulcer / Q000188:drug therapy*; D013312:Stress, Physiological / Q000150:complications; D013392:Sucralfate / Q000627:therapeutic use*
D013392:Sucralfate